Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 271-802-8 | CAS number: 68608-82-2 A complex combination of hydrocarbons obtained by the alkylation of benzene with ethene. It consists primarily of ethylbiphenyls, diethylbenzenes with lesser amounts of butylbenzenes and polyethylbenzenes.
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
'Benzene, ethylenated by-products' was tested in a standard OECD guideline mouse LLNA. At the mid and high doses (50 and 100%) there was an increase in the stimulation index compared to control that exceeded 3x indicating that this substance was capable of inducing proliferation of the lymph nodes at these concentrations. The EC3 value of 30.3% was calculated indicating that this is possibly a very weak sensitiser. In the mid and high dose groups there was also evidence of swelling of the ears relative to control and this is consistent with the irritancy of the test material. It is possible that the result of the local lymph node assay is due to a non-specific induction of lymphnode proliferation rather than a specific sensitising response to this substance. This could be due in part to the irritancy of the material. In the entire history of use of this material there have been no reports of workers becoming sensitised to this substance through dermal exposure. Therefore, whilst this substance may be technically capable of inducing lymphnode cell proliferation in the LLNA, the relevance of that result to humans may be limited.
Migrated from Short description of key information:
Mouse LLNA assay
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Additional information:
There is no data or indication from humans that this substance is a respiratory sensitiser
Migrated from Short description of key information:
No data available
Justification for classification or non-classification
Due to the classification criteria set out in the CLP being limited to the classification as either a sensitiser or not a sensitiser, this substance must be classified as a sensitiser based solely on the positive result in the LLNA. However the EC3 value of >30% indicates that it is a weak sensitiser and so the risk to humans is relatively small. It is also possible that the irritancy of the material and its solvent activity could have produced a non-specific proliferation response in the lymph nodes, but without additional information it is not possible to make a firm judgment. Therefore this substance should be classified as a (weak) sensitiser, Category 1B according to CLP.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
